The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics.
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
James Moon
No Relationships to Disclose
 
Paul Joseph Hesketh
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Stephen K. Williamson
No Relationships to Disclose
 
Fred R. Hirsch
No Relationships to Disclose
 
Philip C. Mack
No Relationships to Disclose
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer